SELLAS Life Sciences Group, Inc. (SLS) Tuesday said that its Phase 2 trial of SLS009 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) met all primary goals.
The Phase 2 study was designed to evaluate SLS009 in combination with venetoclax and azacitidine. The primary endpoint for the trial was overall response rate (ORR). The study exceeded target ORR of 20% with 44% response rate in patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR). Median Overall Survival (mOS) was 8.9 Months, which surpassed the historical median of 2.4 months.
The FDA has recommended SELLAS to include newly diagnosed, first-line AML patients in a study, that may support a New Drug Application. The company plans to initiate the study by the first quarter of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.